AMGN
Price
$287.71
Change
+$2.10 (+0.74%)
Updated
Aug 29 closing price
Capitalization
154.89B
59 days until earnings call
GSK
Price
$39.67
Change
+$0.23 (+0.58%)
Updated
Aug 29 closing price
Capitalization
79.39B
60 days until earnings call
Interact to see
Advertisement

AMGN vs GSK

Header iconAMGN vs GSK Comparison
Open Charts AMGN vs GSKBanner chart's image
Amgen
Price$287.71
Change+$2.10 (+0.74%)
Volume$1.3M
Capitalization154.89B
GSK
Price$39.67
Change+$0.23 (+0.58%)
Volume$3.59M
Capitalization79.39B
AMGN vs GSK Comparison Chart in %
Loading...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMGN vs. GSK commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a StrongBuy and GSK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (AMGN: $287.71 vs. GSK: $39.67)
Brand notoriety: AMGN: Notable vs. GSK: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 66% vs. GSK: 76%
Market capitalization -- AMGN: $154.89B vs. GSK: $79.39B
AMGN [@Pharmaceuticals: Major] is valued at $154.89B. GSK’s [@Pharmaceuticals: Major] market capitalization is $79.39B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 2 FA rating(s) are green whileGSK’s FA Score has 2 green FA rating(s).

  • AMGN’s FA Score: 2 green, 3 red.
  • GSK’s FA Score: 2 green, 3 red.
According to our system of comparison, both AMGN and GSK are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while GSK’s TA Score has 6 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 5 bearish.
  • GSK’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both AMGN and GSK are a good buy in the short-term.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а -2.05% price change this week, while GSK (@Pharmaceuticals: Major) price change was -1.29% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.73%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +12.21%.

Reported Earning Dates

AMGN is expected to report earnings on Oct 29, 2025.

GSK is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMGN($155B) has a higher market cap than GSK($79.4B). AMGN has higher P/E ratio than GSK: AMGN (23.52) vs GSK (17.75). GSK YTD gains are higher at: 21.276 vs. AMGN (13.757). AMGN has higher annual earnings (EBITDA): 15.9B vs. GSK (8.61B). GSK has more cash in the bank: 3.62B vs. AMGN (923M). GSK has less debt than AMGN: GSK (17.4B) vs AMGN (57.4B). AMGN has higher revenues than GSK: AMGN (34.9B) vs GSK (31.6B).
AMGNGSKAMGN / GSK
Capitalization155B79.4B195%
EBITDA15.9B8.61B185%
Gain YTD13.75721.27665%
P/E Ratio23.5217.75133%
Revenue34.9B31.6B110%
Total Cash923M3.62B26%
Total Debt57.4B17.4B330%
FUNDAMENTALS RATINGS
AMGN vs GSK: Fundamental Ratings
AMGN
GSK
OUTLOOK RATING
1..100
621
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
4267
SMR RATING
1..100
1339
PRICE GROWTH RATING
1..100
6155
P/E GROWTH RATING
1..100
9627
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (6) in the Pharmaceuticals Major industry is in the same range as AMGN (15) in the Biotechnology industry. This means that GSK’s stock grew similarly to AMGN’s over the last 12 months.

AMGN's Profit vs Risk Rating (42) in the Biotechnology industry is in the same range as GSK (67) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.

AMGN's SMR Rating (13) in the Biotechnology industry is in the same range as GSK (39) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to GSK’s over the last 12 months.

GSK's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as AMGN (61) in the Biotechnology industry. This means that GSK’s stock grew similarly to AMGN’s over the last 12 months.

GSK's P/E Growth Rating (27) in the Pharmaceuticals Major industry is significantly better than the same rating for AMGN (96) in the Biotechnology industry. This means that GSK’s stock grew significantly faster than AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMGNGSK
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
46%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
51%
Bullish Trend 2 days ago
46%
MACD
ODDS (%)
Bearish Trend 2 days ago
48%
Bullish Trend 2 days ago
48%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 11 days ago
56%
Bullish Trend 4 days ago
58%
Declines
ODDS (%)
Bearish Trend 3 days ago
53%
Bearish Trend 25 days ago
54%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
58%
Bearish Trend 2 days ago
52%
Aroon
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
45%
View a ticker or compare two or three
Interact to see
Advertisement
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CVAR27.700.10
+0.37%
Cultivar ETF
MUSI44.310.01
+0.02%
American Century Multisector Income ETF
SPEM44.40-0.20
-0.45%
SPDR® Portfolio Emerging Markets ETF
AVLC74.37-0.46
-0.61%
Avantis U.S. Large Cap Equity ETF
HERZ2.44-0.04
-1.51%
Herzfeld Credit Income Fund Inc

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
+0.58%
NVS - GSK
67%
Closely correlated
+0.06%
AZN - GSK
63%
Loosely correlated
-0.11%
PFE - GSK
57%
Loosely correlated
+0.65%
SNY - GSK
55%
Loosely correlated
-0.92%
JNJ - GSK
49%
Loosely correlated
+0.98%
More